SAN LUIS OBISPO, California – November 10, 2005 – FzioMed, Inc. announced today that it has obtained the exclusive, worldwide license to a broad platform of patents and intellectual property covering novel, synthetic peptides from the University of Southern California (USC) for use in the regeneration of bone, cartilage and skeletal tissue.
The worldwide license covers proprietary, synthetic oligopeptides that have been studied in a variety of preclinical settings for osteoinduction in bone healing. FzioMed obtained an option to license the novel peptides from USC in 2004. FzioMed has been studying the peptides, in combination with the company’s patented Oxiplex gel as a delivery vehicle, for use in bone growth applications. The promising results of the studies have been reported at leading surgical congresses.
FzioMed has now exercised its option to license the peptide portfolio. The rights include all potential applications for the peptides in the regeneration, repair, growth or augmentation of bone, cartilage and skeletal tissue, in any surgical specialty. FzioMed will pursue development of the peptides across all potential applications. Future products will be designed for use in orthopedic, spine, trauma, joint reconstruction and sports medicine.
“FzioMed sees significant market opportunities for injectable bone growth factors with osteoinductive properties,” said Richard Berg, PhD, Vice President of Research and Development for FzioMed. “These new peptides, combined with our synthetic gels for injectable delivery, will be the basis for FzioMed products that meet an important medical need.”
FzioMed is a privately held medical company engaged in the development and commercialization of synthetic, absorbable biomaterials based on the company’s patented Oxiplex technology. FzioMed is developing products for adhesion prevention, tissue augmentation and regeneration, and the delivery of drugs. Oxiplex is an innovative polymer technology with uses in a variety of specialties including orthopedics, gynecology, general surgery, neurosurgery and aesthetic surgery. FzioMed products include Oxiplex/SP, the leading adhesion barrier for spine surgery currently marketed outside of the United States, Oxiplex/AP adhesion barrier for gynecologic and general surgery, and a cosmetic dermal filler.
FzioMed® and Oxiplex® are registered trademarks of FzioMed, Inc.